News
This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a ...
Asianet Newsable on MSN59m
Novo Nordisk Downgraded By UBS Over Uncertain Outlook For Wegovy, But Retail Prefers To Look At The Sunny SideUBS downgraded Novo Nordisk to ‘Neutral’ from ‘Buy’ with a price target of DKK 340 ($52.59), down from DKK 600. The new price target still implies a near 9% upside to the stock’s closing price on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback